Spotlight on tumor mutational burden in patients with non-small cell lung carcinoma.
作者信息
Ilie Marius, Hofman Paul
机构信息
Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, University Hospital Federation OncoAge, Université Côte d'Azur, Nice, France.
Hospital-Integrated Biobank (BB-0033-00025), Pasteur Hospital, University Hospital Federation OncoAge, Université Côte d'Azur, Nice, France.
出版信息
Transl Lung Cancer Res. 2018 Dec;7(6):614-615. doi: 10.21037/tlcr.2018.08.06.
Abstract
摘要
相似文献
1
Spotlight on tumor mutational burden in patients with non-small cell lung carcinoma.聚焦非小细胞肺癌患者的肿瘤突变负荷
Transl Lung Cancer Res. 2018 Dec;7(6):614-615. doi: 10.21037/tlcr.2018.08.06.
2
Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.循环肿瘤 DNA 肿瘤突变负荷（ctDNA TMB）在非小细胞肺癌中的临床意义。
Oncologist. 2019 Jun;24(6):820-828. doi: 10.1634/theoncologist.2018-0433. Epub 2019 Mar 13.
3
Lung Cancer with a High Tumor Mutational Burden.肿瘤突变负荷高的肺癌
N Engl J Med. 2018 Sep 13;379(11):1093. doi: 10.1056/NEJMc1808566.
4
Lung Cancer with a High Tumor Mutational Burden.肿瘤突变负荷高的肺癌
N Engl J Med. 2018 Sep 13;379(11):1093-1094. doi: 10.1056/NEJMc1808566.
5
A universal method for the mutational analysis of K-ras and p53 gene in non-small-cell lung cancer using formalin-fixed paraffin-embedded tissue.一种使用福尔马林固定石蜡包埋组织对非小细胞肺癌中K-ras和p53基因进行突变分析的通用方法。
Diagn Mol Pathol. 1995 Dec;4(4):266-73. doi: 10.1097/00019606-199512000-00007.
6
Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.利用靶向下一代测序技术来描述小细胞肺癌的肿瘤突变负担和免疫检查点抑制的疗效。
J Immunother Cancer. 2019 Mar 28;7(1):87. doi: 10.1186/s40425-019-0572-6.
7
PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer.程序性死亡配体 1 表达和肿瘤突变负担状态预测非小细胞肺癌对化疗和靶向治疗的反应。
J Exp Clin Cancer Res. 2019 May 14;38(1):193. doi: 10.1186/s13046-019-1192-1.
8
Impact of high tumor mutational burden in solid tumors and challenges for biomarker application.实体瘤中高肿瘤突变负担的影响及生物标志物应用的挑战。
Cancer Treat Rev. 2020 Sep;89:102084. doi: 10.1016/j.ctrv.2020.102084. Epub 2020 Jul 22.
9
[The study of pleural effusion supernatant cell-free tumor DNA in tumor mutational burden assessment of advanced lung cancer].[胸腔积液上清游离肿瘤DNA在晚期肺癌肿瘤突变负荷评估中的研究]
Zhonghua Jie He He Hu Xi Za Zhi. 2019 Aug 12;42(8):596-601. doi: 10.3760/cma.j.issn.1001-0939.2019.08.007.
10
PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.程序性死亡配体 1 表达、肿瘤突变负荷和癌症基因突变是预测非小细胞肺癌免疫检查点阻断获益的更强指标，优于 HLA Ⅰ类基因分型。
J Thorac Oncol. 2019 Jun;14(6):1021-1031. doi: 10.1016/j.jtho.2019.02.008. Epub 2019 Feb 16.
引用本文的文献
1
Targeted next-generation sequencing to assess tumor mutation burden: ready for prime-time in non-small cell lung cancer?靶向二代测序评估肿瘤突变负荷：非小细胞肺癌能否迎来黄金时代？
Transl Lung Cancer Res. 2019 Dec;8(Suppl 4):S323-S326. doi: 10.21037/tlcr.2019.09.01.
本文引用的文献
1
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.新辅助 PD-1 阻断治疗可切除性肺癌。
N Engl J Med. 2018 May 24;378(21):1976-1986. doi: 10.1056/NEJMoa1716078. Epub 2018 Apr 16.
2
Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine?肿瘤突变负荷：将免疫疗法引领至精准医学时代？
J Clin Oncol. 2018 Mar 1;36(7):631-632. doi: 10.1200/JCO.2017.76.8770. Epub 2018 Jan 16.
3
Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy.高突变循环肿瘤 DNA：与基于检查点抑制剂免疫治疗反应的相关性。
Clin Cancer Res. 2017 Oct 1;23(19):5729-5736. doi: 10.1158/1078-0432.CCR-17-1439.
4
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.Durvalumab 用于 III 期非小细胞肺癌放化疗后的治疗。
N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8.
5
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.纳武利尤单抗联合伊匹木单抗作为晚期非小细胞肺癌的一线治疗方案（CheckMate 012）：一项开放标签的1期多队列研究结果
Lancet Oncol. 2017 Jan;18(1):31-41. doi: 10.1016/S1470-2045(16)30624-6. Epub 2016 Dec 5.
6
Genomic Approaches to Understanding Response and Resistance to Immunotherapy.理解免疫疗法反应和耐药性的基因组学方法
Clin Cancer Res. 2016 Dec 1;22(23):5642-5650. doi: 10.1158/1078-0432.CCR-16-0066. Epub 2016 Oct 3.
7
Tumor neoantigens: building a framework for personalized cancer immunotherapy.肿瘤新抗原：构建个性化癌症免疫治疗的框架
J Clin Invest. 2015 Sep;125(9):3413-21. doi: 10.1172/JCI80008. Epub 2015 Aug 10.
8
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.癌症免疫学。突变图谱决定非小细胞肺癌对程序性死亡受体1（PD-1）阻断治疗的敏感性。
Science. 2015 Apr 3;348(6230):124-8. doi: 10.1126/science.aaa1348. Epub 2015 Mar 12.
9
Mutational heterogeneity in cancer and the search for new cancer-associated genes.癌症中的突变异质性与新的癌症相关基因的寻找。
Nature. 2013 Jul 11;499(7457):214-218. doi: 10.1038/nature12213. Epub 2013 Jun 16.
Zotero 插件